🧭 Guided View New to genetics? We explain every term as you browse, in plain English. Same pages, with the help built in.
⚡ Expert View You already know the biology. Just the content — clean and compact, no extra explanations. This is the default view.
Interface language
Light mode
Treatment · Cancer
CB-010
An allogeneic CAR-T candidate built with hybrid RNA-DNA guides rather than conventional guide RNAs, intended to cut off-target editing.
Phase Icell therapyallogeneicCas12a
Clinical researchBeing tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
Simple explanation
Caribou builds its edited cells using a modified kind of guide — part RNA, part DNA — which the company says makes the editing machinery fussier about where it cuts. CB-010 is an off-the-shelf CAR-T made this way, with an extra edit that removes a brake on the engineered cells so they keep working longer.
Go deeper
CB-010 is an allogeneic anti-CD19 CAR-T candidate from Caribou Biosciences produced using chRDNA (hybrid CRISPR RNA-DNA) guides with Cas12a, incorporating TRAC insertion of the CAR and PDCD1 knockout to improve persistence. In development for B-cell non-Hodgkin lymphoma and autoimmune indications.
Educational information only
This page is a reference, not medical advice. Research and regulatory status change; check the last-updated date above and confirm anything important against the primary sources listed.